Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom.
about
Gloves, gowns and masks for reducing the transmission of meticillin-resistant Staphylococcus aureus (MRSA) in the hospital settingCommunity-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemicCurrent concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococciMRSA: treating people with infection.Zero tolerance for healthcare-associated MRSA bacteraemia: is it realistic?Association of methicillin-resistant Staphylococcus aureus (MRSA) USA300 genotype with mortality in MRSA bacteremiaClinical management of Staphylococcus aureus bacteremia: a review.Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycinEmergence of SCCmec Type I Obtained From Clinical Samples in Shiraz Teaching Hospitals, South-West of Iran.Systematic Surveillance Detects Multiple Silent Introductions and Household Transmission of Methicillin-Resistant Staphylococcus aureus USA300 in the East of EnglandClinical characteristics of pediatric patients hospitalized with methicillin-resistant Staphylococcus aureus in Canadian hospitals from 2008 to 2010.Methicillin-resistant Staphylococcus aureus in community-acquired and health care-associated pneumonia: incidence, diagnosis, and treatment options.Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia.Complicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin.Antibiotic resistance rates in causative agents of infections in diabetic patients: rising concerns.MRSA in Croatia: prevalence and management.Establishment of an AUC0-24 Threshold for Nephrotoxicity Is a Step towards Individualized Vancomycin Dosing for Methicillin-Resistant Staphylococcus aureus Bacteremia.Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.Antimicrobial resistance in healthcare, agriculture and the environment: the biochemistry behind the headlines.Isolation of a small molecule with anti-MRSA activity from a mangrove symbiont Streptomyces sp. PVRK-1 and its biomedical studies in Zebrafish embryosMethicillin resistance & inducible clindamycin resistance in Staphylococcus aureus.Staphylococcus aureus bacteraemia associated with injected new psychoactive substances.Sustained release of vancomycin from novel biodegradable nanofiber-loaded vascular prosthetic grafts: in vitro and in vivo study.Evaluation of High-Dose Daptomycin Versus Vancomycin Alone or Combined with Clarithromycin or Rifampin Against Staphylococcus aureus and S. epidermidis in a Novel In Vitro PK/PD Model of Bacterial Biofilm.Production of a compound against methicillin resistant Staphylococcus aureus (MRSA) from Streptomyces rubrolavendulae ICN3 & its evaluation in zebrafish embryosEconomic evaluation of treatment for MRSA complicated skin and soft tissue infections in Glasgow hospitals.CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.Antimicrobial-resistant pathogens in animals and man: prescribing, practices and policies.Clinical experience with daptomycin in Italy: results from a registry study of the treatment of Gram-positive infections between 2006 and 2009.Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA).Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries.The mechanism of antibacterial activity of phlorofucofuroeckol-A against methicillin-resistant Staphylococcus aureus.Methicillin-resistant Staphylococcus aureus bacteremia among liver transplant recipients: epidemiology and associated risk factors for morbidity and mortality.In VitroAntibacterial Activity and Synergistic Antibiotic Effects of Phlorotannins Isolated fromEisenia bicyclisAgainst Methicillin-ResistantStaphylococcus aureusPneumonia Caused by Community-Acquired Methicillin-Resistant : Vancomycin or Linezolid?Clinical outcomes after initial treatment of methicillin-resistant infectionsTiming of initiating glycopeptide therapy for methicillin-Resistant Staphylococcus aureus bacteremia: the impact on clinical outcomeManagement of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics
P2860
Q24186422-F47822D8-9153-4A3A-AE57-F7F7E36E21D8Q24614464-CB989F22-F3FE-4946-8BFF-F6C72B58A211Q26853465-CAE443D0-E59B-45D0-88B4-68DF45F82EE1Q33850476-0913DDA4-84A3-4088-9D90-107413ADB8B2Q33910015-55269680-FE9E-4D59-8855-0C07617E2C9BQ34288755-F49235BF-F31D-40F2-A659-E4F0CA3EB55FQ34441035-16993DE0-4271-41B3-866E-930DB40CC445Q34478074-7F822A32-9403-4AE5-AE89-7D33207BE852Q35959558-05EE3B3D-0D04-47A2-99CF-691DD6DB27C6Q35996066-26585A26-DEC3-4F15-98E5-9B6CCC43397EQ37074618-DF20F195-401E-4B1E-BEB1-D801ECA59F0AQ37366769-3ADC7AB9-EAB6-4C10-BB0D-7CBF242215ECQ37752231-04D3E70F-727B-4698-A68C-13E603A55954Q37800310-CE5C828D-2171-4115-B5EB-E8CF2A32104CQ37900838-780FBF33-1666-4C32-9359-88EE821414F2Q38097122-81B54A32-CF82-4FD3-848D-A3DE1B20433CQ38631043-26952A76-703D-462D-B5E9-E2D50FCA0990Q38938708-0989B1BA-AA5A-4C49-8F7B-93D8637C7BDEQ38987098-41C2515D-C366-4816-A0AC-1479C8388EE4Q39160453-6FF7F9AC-0415-4DD1-B5D5-ADB54885670BQ39508946-36434697-78FF-40CE-8672-8584A5BCD556Q40653080-49CD27E1-19D1-4AF5-9A2D-F98224A063F2Q40918288-1341A24A-663D-43EE-945D-FA3F685192BFQ41447169-A8C35CF8-FFE7-4171-8B34-6CB13DBB791BQ41593734-93AAF0B5-13E2-4ECA-928A-7462CA9EF5FEQ41996402-5142AC23-DB8C-4AC4-A412-3AF0CDE3A900Q42249120-5231915F-C74F-46BF-B5CC-154A09AEFC3EQ42790613-F960B0A4-E1FB-4ACF-8C18-9351C40089C5Q45034218-55934292-27CE-4336-963C-0FA6965A1157Q47828777-BBA8342A-F91B-4F19-91E8-9F14F062D1D6Q49833719-474C0BEA-4276-4871-B965-6DB70299C2C1Q53654914-0F0B9EAE-FD78-468B-8DEE-86DFCDEA66D5Q54190309-1C91F76E-3DEF-47D8-8E9D-59ED403D8894Q54210717-0337E67D-1A32-49B6-A099-3E33BF307F0DQ57846985-318BFBB0-0A47-4349-AF69-87589F17D4E0Q58765851-F6A24547-01D1-4C18-AD82-2D81B58446EEQ58799236-C53C3692-2396-4CA9-8A1C-ACA5B5A0E63CQ59033824-C2E574F3-D9A9-4EEC-97BE-C0C197C82DC4Q59135453-35753E6D-8296-4EE4-A404-6C3AD4FA8BC5
P2860
Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Guidelines (2008) for the prop ...... ections in the United Kingdom.
@en
Guidelines
@nl
type
label
Guidelines (2008) for the prop ...... ections in the United Kingdom.
@en
Guidelines
@nl
prefLabel
Guidelines (2008) for the prop ...... ections in the United Kingdom.
@en
Guidelines
@nl
P2093
P2860
P356
P1476
Guidelines (2008) for the prop ...... ections in the United Kingdom.
@en
P2093
Adam P Fraise
Dilip Nathwani
F Kate Gould
Geoff L Ridgway
MRSA Working Party of the British Society for Antimicrobial Chemotherapy
Michael J Spry
Paul R Chadwick
Richard Brindle
Rod E Warren
Simon Hill
P2860
P304
P356
10.1093/JAC/DKP065
P407
P577
2009-03-12T00:00:00Z